The actual approaches to therapy of refractory migraine


Cite item

Full Text

Abstract

The refractory migraine is a severe version of migraine with many unclear and contradictory related issues. The main problem of such patients is in absent or minimal effect of standard anti-migraine therapy both in prevention of attack and rapid relief of symptoms. Hence the most difficulties are related to tactics of management of hard-curable patients with refractory migraine. The therapy is more often selected in empirical way and individually for every patient. This process takes much more than one month and the main purpose of treatment is to decrease level of deadaptation. In this connection, during management of this category of patients the most justified is multidisciplinary approach coupled with rational combined pharmacological therapy with large specter of non-pharmaceutical methods of exposure.

About the authors

Eugenia V. Ekusheva

The I.M. Sechenov first Moscow medical university of Minzdrav of Russia

Email: ekushevaev@mail.ru
The laboratory of pathology of vegetative nervous system of the research department Moscow, Russia

I. V Damulin

The I.M. Sechenov first Moscow medical university of Minzdrav of Russia

Email: damulin@mmascience.ru
доктор мед. наук, профессор, кафедра нервных болезней лечебного факультета 119992, Moscow, Russia

References

  1. Филатова Е.Г., Вейн А.М. Мигрень. Consilium medicum. 1999; 1(2): 60-5.
  2. Levin М., Schulman Е. Refractory migraine: definition and classification. In: Schulman E.A., Levin M., Lake A.E. et al. Refractory migraine. Mechanisms and management. New York: Oxford University Press; 2010: 19-34.
  3. Scher A.I., Stewart W.F., Ricci J.A. et. al. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003; 106: 81-9.
  4. Katsarava Z., Schneeweiss Kurth T., Kroener U. et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004; 62: 788-90.
  5. Lipton R.B., Bigal M.E. Epidemiology of refractory migraine. In: Schulman E.A., Levin M., Lake A.E. et al. Refractory migraine. Mechanisms and management. New York: Oxford University Press; 2010: 35-45.
  6. Palmisani S., Al-Kaisy A., Arcioni R. et al. A six year retrospective review of occipital nerve stimulation practice - controversies and challenges of an emerging technique for treating refractory headache syndromes. J. Headache Pain. 2013; 14 (1): 67.
  7. Headache Classification Committee of the International Headache Society. The International classification of headache disorders. 3rd ed. (betaversion). Cephalagia. 2013; 33: 629-808.
  8. Headache Classification Committee of the International Headache Society. The International classification of headache disorders. 2nd ed. Cephalagia. 2004; 24(Suppl. 1): 1-160.
  9. Irimia P., Palma J.A., Fernandez-Torron R., Martinez-Vila E. Refractory migraine in a headache clinic population. BMC Neurol. 2011; 11: 94.
  10. Evans R.W. A rational approach to the management of chronic migraine. Headache. 2013; 53: 168-76.
  11. Екушева Е.В. Оптимальные подходы к купированию приступа мигрени: прошлое, настоящее и будущее. Русский медицинский журнал. 2012; 10: 522-8.
  12. Critchley M. Migraine: From Cappadoccia to Queen Square. In: Smith R., ed. Background to migraine. vol. 1. London: Heinemann; 1967: 28-38.
  13. Schulman E.A., McGeeney B.E. Current concepts in refractory migraine. Curr. Treat. Opitions Neurol. 2013; 15(1): 40-55.
  14. Schulman E.A., Traumuta G. Refractory headache. Headache. 1993; 33: 273-86.
  15. Goadsby P.J., Hargreaves R. Refractory migraine and chronic migraine: pathophysiological mechanisms. Headache. 2008; 48(6): 799-804.
  16. Robbins L. Refractory chronic migraine. Pract. Pain Manag. 2010; 10: 10-24.
  17. Robbins L. Refractory chronic migraine: longterm follow-up using a refractory rating scale. J. Headache Pain. 2012; 13: 225-9.
  18. Dodick D.W. Reflections and speculations on refractory migraine: why do some patients fail to improve with currently available therapies. Headache. 2008; 46(6): 828-37.
  19. Silberstein S.D., Dodick D.W., Pearlman S. Defining the pharmacologically interactable headache for clinical trials and clinical practice. Headache. 2010; 50: 1499-506.
  20. Ashina S., Serrano D., Lipton R.B. et. al. Depression and risk of transformation of episodic to chronic migraine. J. Headache Pain. 2012; 13: 615-24.
  21. Bigal M.E., Serrano D., Reed M. et. al. Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology. 2008; 71: 559-66.
  22. Mathew N.T. Prophylactic treatment of refractory migraine. In: Schulman E.A., Levin M., Lake A.E. et al. Refractory migraine. Mechanisms and management. New York: Oxford University Press; 2010: 101-16.
  23. Азимова Ю.Э., Маргулис М.И., Табеева Г.Р. Рефрактерная мигрень: от патогенеза к рациональной терапии. Русский медицинский журнал. 2011; 1: 18-9.
  24. Tepper S.J., Tepper D.E. Medication overuse headache in refractory migraine and its treatment. In: Shulman E.A., Levin M., Lake A.E. et al. Refractory migraine. Mechanisms and management. New York: Oxford: University Press; 2010: 136-60.
  25. Krymchantowski A.V., Jevoux C.C. Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective "real-world" study. Headache. 2011; 51(4): 554-8.
  26. Krymchantowski A.V., Jevoux C.C. Low-dose topiramate plus sodium divalproate for positive responders intolerant to full-dose monotherapy. Headache. 2012; 52(1): 129-32.
  27. Cady R.K., Schreiber C.P., Porter J.A. et al. A multi-center doubleblind pilot comparison of оnabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011; 51: 21-32.
  28. Dodick D.W., Turkel C.C., DeGryse R. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the doubleblind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010; 50: 921-36.
  29. Mathew N.T., Jaffri S.F. A double-blind comparison of onabotulinumtoxinА (BOTOX®) and topiramate (TOPAMAX®) for the prophylactic treatment of chronic migraine: a pilot study. Headache. 2009; 49: 1466-78.
  30. Oterino A., Ramon C., Pascual J. Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks. J. Headache Pain. 2012; 12: 235-8.
  31. Tepper S.J., Bigal M.E., Sheftell F.D. et al. Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases. Headache. 2004; 44(8): 794-800.
  32. Krymchantowski A.V., Jevoux С.С., Moreira P.F. An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine. Pain Med. 2010; 11(1): 48-52.
  33. Ashkenazi A., Benlifer A., Korenblit J. et al. Zonizamide for migraine prophpylaxis inrefractory patients. Cephalalgia. 2006; 26: 1199-202.
  34. Bermejo P.E., Dorado R. Zonizamide for migraine prophylaxis in patients refractory to topiramate. Clin. Neuropharmacol. 2009; 32: 103-6.
  35. Pascual-Gomez J., Gracia-Naya M., Leira R. et al. Zonisamide in the preventive treatment of refractory migraine. Rev. Neurol. 2010; 50: 129-32.
  36. Maizels M. Clonazepam for refractory headache: three cases illustrative of benefit and risk. Headache. 2010; 50: 650-6.
  37. Krymchantowski A., Jevoux С.С. Memantine in the preventive treatment for migraine and refractory migraine. Headache. 2009; 49: 481-2.
  38. Togha M., Rahmat J.M. et al. Cinnarizine in refractory migraine prophylaxis: efficacy and tolerability. A comparison with sodium valproate. J. Headache Pain. 2008; 9: 77-82.
  39. Lovell B.V., Marmura M.J. New therapeutic developments in chronic migraine. Curr. Opin. Neurol. 2010; 23: 254-8.
  40. Rothrock J.F. Treatment refractory migraine: the case for opioid therapy. Headache. 2008; 48: 850-4.
  41. Екушева Е.В., Филатова Е.Г. Залдиар в лечении приступов мигрени. Журнал неврологии и психиатрии им. С.С. Корсакова. 2007; 107: 74-6.
  42. McGeeney B.E. Acute and urgent treatment of refractory migraine. In: Shulman E.A., Levin M., Lake A.E. et.al. Refractory migraine. Mechanisms and management. New York: Oxford University Press; 2010: 116-36.
  43. Levin M. Opioids in headache.Headache. 2013; 48(6): 783-90.
  44. Robbins L. Long-acting opioids for refractory chronic migraine. Pract. Pain Manag. 2009; 9(6): 74-8.
  45. Rapoport A.M., Bigal M.E., Volcy M. et al. Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases. Headache. 2003; 43(5): 482-9.
  46. Sheftell F.D., Rapoport A.M., Tepper S.J. et al. Naratriptan in the preventive treatment of refractory transformed migraine: a prospective pilot study. Headache. 2005; 45(10): 1400-6.
  47. Tobin J., Filtman S. Occipital nerve blocks: when and what to inject? Headache. 2009; 49: 1521-33.
  48. Weibelt S., Andress-Rothrock D., King W. et. al. Suboccipital nerve blocks for suppression of chronic migraine: safety, efficacy, and predictors of outcome. Headache. 2010; 50: 1041-4.
  49. Krusz J.C. Belanger J., Cagle J. Treatment of refractory migraines: high success rate in the clinic. Poster Abstract. 49th Annual Scientific Meeting of the American Headache Society. Chicago. Headache. 2007; 47: 752.
  50. Schulman Е. Historical overview of refractory headache. In: Shulman E.A., Levin M., Lake A.E. et al. Refractory migraine. Mechanisms and management. New York: Oxford University Press; 2010: 5-18.
  51. Dodick D.W. Triptan nonresponder studies: implications for clinical practice. Headache. 2005; 45: 156-62.
  52. Ifergane G., Wirguin I., Shvartzman P. Triptans - why once? Headache. 2006; 46(8): 1261-3.
  53. Krymchantowski A.V., Barbosa J.S. Dexamethasone decreases migraine recurrence observed after treatment with a triptan combined with a nonsteroidal anti-inflammatory drug. Arq. Neuropsiquiatr 2001; 59(3-В): 708-11.
  54. Азимова Ю.Э. Рефрактерная мигрень. Фарматека. 2012; 12: 50-3.
  55. Nagy A.J., Gandhi S., Bhola R. et al. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011; 77: 1827-32.
  56. Aurora S.K., Silberstein S.D., Kori S.H. et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011; 51: 507-17.
  57. Bigal M.E., Rapoport A.M., Sheftell F.D. et al. Transformed migraine and medication overuse in a tertiary headache center - clinical characteristics and treatment outcomes. Cephalalgia. 2004; 24: 483-90.
  58. Bigal M.E., Lipton R.B. What predict the change from episodic to chronic migraine. Curr. Opin. Neurol. 2009; 22: 269-76.
  59. Breslau N., Lipton R.B., Stewart W.F. et al. Comorbidity of migraine and depression: Investigating potential etiology and prognosis. Neurology. 2003; 60: 1308-12.
  60. Lake A.E., Saper J.R., Hamel R.L. Comprehensive inpatient treatment of refractory chronic daily headache. Headache. 2009; 49: 555-62.
  61. Saper J.R., Lake A.E. Inpatient strategies for refractory migraine. In: Shulman E.A., Levin M., Lake A.E. et al. Refractory migraine. Mechanisms and management. New York: Oxford University Press; 2010: 314-41.
  62. Franzini A., Messina G., Leone M. et al. Occipital nerve stimulation (ONS). Surgical technique and prevention of late electrode migration. Acta Neurochir. (Wien). 2009; 151: 861-5.
  63. Silberstein S.D., Dodick D.W., Saper J. et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2012; 32: 1165-79.

Copyright (c) 2014 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies